olivLaw · US equity research
DNA X, Inc. SONM
Telephone & Telegraph Apparatus · SIC 3661 · Vertical: Telephone & Telegraph Apparatus (SIC 3661)
DNA X, Inc. (formerly Sonim Technologies) exited its phone and hotspot business and now focuses on its cryptocurrency trading platform, which was closed to the public in March 2026 for development and is due to relaunch in the fourth quarter of 2026. The key question is whether the platform can return to meaningful trading volume after relaunch, while commission revenue is still very small.
At the close of 05 Nov 2026, DNA X, Inc. (SONM) stock was 2.30 USD (−10.51% on the day), with market capitalisation 3.4 m USD, beta 1.29, 52-week range 2.30–11.51 USD. Latest reported quarter (Q2 2026): net income of -1.2 m USD, diluted EPS -0.92 USD.
Data as of · AI analysis dated · Source: SEC filings and closing prices, computed by olivLaw.
Price history
Loading chart…
Technical reading
- RSI (14)
- 26.3
- oversold (≤ 30)
- Bollinger (20, 2)
- 2.35 – 3.67
- below the lower band · %B -0.04 · band width 43.9%
- SMA 50 / 200
- 3.38 / 4.13
- downtrend (price < SMA50 < SMA200)
- MACD (12, 26, 9)
- -0.29 / -0.22
- MACD below signal
Indicators describe past prices; on their own they do not predict direction. On our history the RSI ≤ 40 filter added no return (see the signals methodology).
Performance
| Company | S&P 500 | vs S&P 500 | Vertical median | |
|---|---|---|---|---|
| 1 month | −42.4% | −5.9% | −36.4 pp | — |
| 3 months | −41.9% | −4.6% | −37.3 pp | — |
| 6 months | −54.3% | +0.2% | −54.5 pp | — |
| Year to date | −27.0% | +7.4% | −34.4 pp | — |
| 1 year | −80.1% | +8.2% | −88.3 pp | −15.0% |
| 3 years | −98.1% | +68.4% | −166.6 pp | −21.0% |
| 5 years | −99.4% | +56.5% | −155.9 pp | — |
Price returns, dividends excluded.
Quarterly results
Latest quarter: Q2 2026 · 30 Jun 2026
Quarterly margins
Quarterly statements · USD
| Fiscal year | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 15.0 m | 15.0 m | 16.7 m | 11.2 m | 16.2 m | — | — | — |
| Cost of revenue | 10.8 m | 15.2 m | 8.4 m | 10.3 m | 14.4 m | — | — | — |
| Gross profit | 4.2 m | -183.0 k | 8.4 m | 845.0 k | 1.8 m | — | — | — |
| Research & development | 715.0 k | 12.5 m | 1.6 m | 909.0 k | 181.0 k | — | — | — |
| Operating income | -2.4 m | 8.4 m | -870.0 k | -1.5 m | -4.0 m | 4.7 m | -3.6 m | -1.3 m |
| Depreciation & amortisation | 918.0 k ≈ | 914.0 k | 1.1 m | 797.0 k ≈ | 952.0 k ≈ | 1.5 m | — | — |
| Interest expense | — | — | 71.0 k | 161.0 k | 339.0 k | 374.0 k | 131.0 k | — |
| Pre-tax income | -2.4 m | 8.9 m | -961.0 k | -1.9 m | -4.7 m | 3.5 m | -3.9 m | -1.2 m |
| Income tax | 117.0 k | -53.0 k | 132.0 k | 138.0 k | 90.0 k | -1.5 m | 2.5 m | -243.0 k |
| Net income | -2.5 m | -21.6 m | 458.0 k | -7.5 m | -4.8 m | -8.9 m | 6.3 m | -1.2 m |
| Diluted EPS | -9.32 | -79.45 ≈ | 1.41 | -14.15 | -4.83 | -8.53 ≈ | 5.01 | -0.92 |
| Operating cash flow | -417.0 k ≈ | -4.5 m | -9.6 m | -4.9 m ≈ | -7.0 m ≈ | -2.0 m | -3.5 m | -2.0 m ≈ |
| Capex | 137.0 k ≈ | 8.0 k | — | — | — | — | — | — |
≈ derived quarter (cumulative difference / share-days average)
E/P over time
E/P = trailing-12-month diluted EPS / price at quarter end. E/P is the inverse of P/E and stays defined when earnings are negative.
Fiscal years
| Fiscal year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 135.7 m | 116.3 m | 64.0 m | 54.6 m | 69.8 m | 93.6 m | 58.3 m | unavailable |
| Revenue YoY | unavailable | −14.3% | −45.0% | −14.7% | +28.0% | +34.1% | −37.7% | unavailable |
| Net income | 1.3 m | -25.8 m | -29.9 m | -38.6 m | -14.1 m | -90.0 k | -33.6 m | -20.7 m |
| Net income YoY | unavailable | −2,123.0% | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable |
| Diluted EPS | unavailable | unavailable | unavailable | -4.08 | -0.49 | -0.02 | -128.37 | -28.58 |
| Diluted EPS YoY | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable |
| net % | 0.9% | -22.2% | -46.8% | -70.8% | -20.2% | -0.1% | -57.7% | unavailable |
| Free cash flow | 3.1 m | -34.5 m | -10.6 m | -38.5 m | -12.4 m | -4.1 m | -8.7 m | unavailable |
Reported results vs expectations
Loading…
Balance sheet & financial health
Fiscal year 2025 · 31 Dec 2025
- Cash
- 1.3 m USD
- Financial debt
- 10.1 m USD
- Net debt
- 8.8 m USD
- Equity
- -8.0 m USD
- Total assets
- 43.9 m USD
- Debt / equity
- unavailable
- Current ratio
- 0.57x
- ROE
- unavailable
- ROA
- -49.4%
- FCF margin
- unavailable
Financial statements (source on every figure)
Revenue and net income (USD)
Margins
Income statement · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Revenue | 64.0 m | 54.6 m | 69.8 m | 93.6 m | 58.3 m | — | SEC (XBRL)· 31 Mar 2025verified |
| Cost of revenue | 48.8 m | 48.2 m | 58.2 m | 74.3 m | 48.4 m | — | SEC (XBRL)· 31 Mar 2025verified |
| Gross profit | 15.2 m | 6.4 m | 11.6 m | 19.3 m | 9.9 m | — | SEC (XBRL)· 31 Mar 2025verified |
| Research & development | 16.2 m | 17.7 m | 8.0 m | 1.8 m | 14.2 m | — | SEC (XBRL)· 31 Mar 2025verified |
| Operating income | -29.3 m | -38.0 m | -14.3 m | 513.0 k | -3.1 m | -5.4 m | SEC (XBRL)· 15 Apr 2026verified |
| Depreciation & amortisation | 2.7 m | 2.1 m | 2.4 m | 2.2 m | 3.6 m | 4.3 m | SEC (XBRL)· 15 Apr 2026verified |
| EBITDA | -26.5 m ≈ | -35.9 m ≈ | -11.9 m ≈ | 2.7 m ≈ | 457.0 k ≈ | -1.1 m ≈ | SEC (XBRL)· 15 Apr 2026derived |
| Interest expense | — | — | 97.0 k | — | — | 945.0 k | SEC (XBRL)· 15 Apr 2026verified |
| Pre-tax income | -30.5 m | -38.5 m | -13.9 m | 284.0 k | -2.9 m | -8.0 m | SEC (XBRL)· 15 Apr 2026verified |
| Income tax | -521.0 k | 167.0 k | 184.0 k | 374.0 k | 226.0 k | -1.1 m | SEC (XBRL)· 15 Apr 2026verified |
| Net income | -29.9 m | -38.6 m | -14.1 m | -90.0 k | -33.6 m | -20.7 m | SEC (XBRL)· 15 Apr 2026verified |
| Diluted EPS | — | -4.08 | -0.49 | -0.02 | -128.37 | -28.58 | SEC (XBRL)· 15 Apr 2026verified |
| Weighted average diluted shares | — | — | 28.9 m | 4.3 m | 262.1 k | 722.7 k | SEC (XBRL)· 15 Apr 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Operating income + Depreciation & amortisation.
Balance sheet · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Cash | 22.1 m | 11.2 m | 13.2 m | 9.4 m | 5.3 m | 1.3 m | SEC (XBRL)· 15 Apr 2026verified |
| Receivables | 4.2 m | 10.8 m | 22.4 m | 25.3 m | 4.3 m | — | SEC (XBRL)· 31 Mar 2025verified |
| Inventories | 11.3 m | 5.5 m | 3.9 m | 6.5 m | 10.6 m | — | SEC (XBRL)· 31 Mar 2025verified |
| Current assets | 45.6 m | 35.7 m | 43.6 m | 43.8 m | 32.2 m | 28.9 m | SEC (XBRL)· 15 Apr 2026verified |
| Property, plant & equipment, net | 843.0 k | 534.0 k | 168.0 k | 71.0 k | 227.0 k | — | SEC (XBRL)· 31 Mar 2025verified |
| Total assets | 50.3 m | 41.1 m | 53.7 m | 56.0 m | 39.7 m | 43.9 m | SEC (XBRL)· 15 Apr 2026verified |
| Accounts payable | 8.9 m | 9.5 m | 21.1 m | 19.8 m | 738.0 k | 4.0 m | SEC (XBRL)· 15 Apr 2026verified |
| Short-term debt | 177.0 k | 148.0 k | 147.0 k | — | — | 5.1 m | SEC (XBRL)· 15 Apr 2026verified |
| Long-term debt | 185.0 k | 66.0 k | — | — | — | 5.1 m | SEC (XBRL)· 15 Apr 2026verified |
| Current liabilities | 20.5 m | 21.0 m | 32.1 m | 32.1 m | 43.7 m | 50.6 m | SEC (XBRL)· 20 May 2026verified |
| Total liabilities | 21.9 m | 22.5 m | 33.6 m | 33.7 m | 45.4 m | 50.6 m | SEC (XBRL)· 15 Apr 2026verified |
| Equity | 28.4 m † | 18.6 m † | 20.0 m † | 22.4 m † | -5.7 m † | -8.0 m † | SEC (XBRL)· 15 Apr 2026verified |
† equity attributable to the parent's shareholders: in these years the issuer no longer reports the total including non-controlling interests.
Cash flow · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -10.6 m | -38.5 m | -12.4 m | -4.1 m | -8.5 m | -23.5 m | SEC (XBRL)· 15 Apr 2026verified |
| Capex | 11.0 k | 46.0 k | 8.0 k | 36.0 k | 214.0 k | — | SEC (XBRL)· 31 Mar 2025verified |
| Free cash flow | -10.6 m ≈ | -38.5 m ≈ | -12.4 m ≈ | -4.1 m ≈ | -8.7 m ≈ | — | SEC (XBRL)· 31 Mar 2025derived |
| Investing cash flow | -11.0 k | -46.0 k | -8.0 k | -36.0 k | -214.0 k | — | SEC (XBRL)· 31 Mar 2025verified |
| Financing cash flow | 21.4 m | 27.6 m | 14.3 m | 272.0 k | 4.6 m | 19.5 m | SEC (XBRL)· 15 Apr 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Operating cash flow − Capex.
Computed indicators
Growth
Profitability
Returns
Balance sheet
Liquidity
Cash
Efficiency
Market and valuation
4 indicators that do not apply to the sector.
Valuation
olivLaw classification
- indicators available: 5 of at least 6
- score weight coverage: 51.1% of at least 60%
- valuation methods computed: 0 of at least 1
A scoring methodology on indicators and valuation, not investment advice.
Closing price
05 Nov 2026Source: olivLaw, closing series
Market cap: 3.4 m USD
Key indicators
Coverage and freshness
Score by group
51% · Insufficient data
Estimated value range
unavailable — no valuation method could be computed
Valuation assumptions are editorial choices, not measured; beta is not measured.
Valuation methods
- DCF (discounted cash flow)unavailable · the input exists, but its latest figure is far older than the latest reported period: not used
- Peers: EV/Salesunavailable · net debt missing: EV cannot be bridged to equity (missing debt is not zero)
- Peers: EV/EBITDAunavailable · net debt missing: EV cannot be bridged to equity (missing debt is not zero)
no valuation method could be computed
Classification (SIC) comparables group by industry code, not by economic activity; the direct group is an editorial selection by activity. Members' multiples are on their own trailing twelve months, at their own latest close.
Assumptions (illustrative, editorial)
- Risk-free rate
- 4.3%
- Equity risk premium
- 5.0%
- Beta (default)
- 1.00
- Cost of equity
- 9.3%
- Terminal growth
- 2.5%
Factor scorecard
Insufficient data
Minimum-evidence gate: indicators available: 5 of at least 6; score weight coverage: 51.1% of at least 60%; valuation methods computed: 0 of at least 1
| Factor | Value | Score | Weight used |
|---|---|---|---|
| Gross margin · Quality | 18.3% | 0 (on a fixed band) | 21% |
| EBIT margin · Quality | -7.1% | 17 (vs peers) | 17% |
| FCF margin · Quality | unavailable | unavailable | — |
| Revenue CAGR 3Y · Growth | 2.2% | 9 (on a fixed band) | 33% |
| Revenue growth (YoY) · Growth | -37.7% | 0 (vs peers) | 17% |
| Net debt / EBITDA · Balance sheet | unavailable | unavailable | — |
| Current ratio · Balance sheet | 0.6x | 0 (on a fixed band) | 13% |
| EV/Sales · Valuation | unavailable | unavailable | — |
| FCF yield · Valuation | unavailable | unavailable | — |
| Shareholder yield (distributions) · Returns | unavailable | unavailable | — |
Factors without a value were dropped; the remaining weights were renormalised.
Score groups
- Balance sheet· partial0/100 · 1/2 factors with a value
- Growth6/100 · 2/2 factors with a value
- Quality7/100 · 2/3 factors with a value
- Returns· partialunavailable · 0/1 factors with a value
- Valuation· partialunavailable · 0/2 factors with a value
A «partial» group is computed from under half of its weight or from one factor: it is not a full assessment of the group.
Memo
DNA X, Inc. (SONM). Latest full fiscal year: 2024; data up to 2026-06-30.
Figures computed from the financial statements: revenue 58.3 m USD in 2024; YoY growth -37.7%; net margin -14.5%.
Valuation cannot be computed from the available data.
Insufficient data for a verdict (indicators available: 5 of at least 6; score weight coverage: 51.1% of at least 60%; valuation methods computed: 0 of at least 1).
Text generated deterministically from the figures shown; no language model. Not investment advice.
What supports the thesis
No signal among the computed factors. That is not an absence of risk: factors without data were not assessed, and business risks (margins, inventory, demand) are in the source-based analysis.
What contradicts it
- Gross margin: 18.3%
- EBIT margin: -7.1%
- Revenue CAGR 3Y: 2.2%
- Revenue growth (YoY): -37.7%
- Current ratio: 0.6x
Not assessed (insufficient data or a ratio without meaning): FCF margin, Net debt / EBITDA, EV/Sales, FCF yield, Shareholder yield (distributions).
Versus the vertical median
Telephone & Telegraph Apparatus (SIC 3661) · same industry (4-digit SIC) · compared with 7 companies
Multiples and returns vs the median
Price rebased to 100 (monthly, 5 years)
Companies in the vertical
| Market cap | P/E | ROE | Net margin | Revenue YoY | 1A / 3A | |
|---|---|---|---|---|---|---|
| CIENCiena Corp | 32.7 bn | 51.5 | 22.4% | 10.9% | +18.8% | +13% / +403% |
| FNFabrinet | 10.5 bn | 22.1 | 21.0% | 9.4% | +35.7% | −36% / +81% |
| CLFDClearfield, Inc. | 390.1 m | — | -2.8% | -4.7% | +19.6% | −2% / +13% |
| ADTNADTRAN Holdings, Inc. | 336.6 m | — | -19.2% | -2.2% | +17.5% | −48% / −21% |
| AUDCAudiocodes Ltd. | 207.2 m | 24.7 | 4.9% | 3.6% | +1.4% | −15% / −32% |
| FKWLFranklin Wireless Corp. | 26.3 m | — | -14.9% | -13.0% | −20.8% | −50% / −23% |
| CLROClearone Inc | 12.1 m | — | -275.7% | — | unavailable | −14% / −63% |
| SONMDNA X, Inc. | 3.4 m | — | — | -14.5% | −37.7% | −80% / −98% |
1- and 3-year price returns: for SONM from daily closes (the same as the performance table), for the other companies from month-end closes.
olivLaw engine forecast
The world engine ran after the company's latest material disclosure. Probabilities are of TOUCHING a level within the horizon (not closing there) and sit next to the random walk (p_rw), the no-information benchmark.
The engine has no published run for this company yet.
Valuation scenarios (editable assumptions)
Illustrative scenarios
Illustrative: not forecasts and without probabilities. Each case is one coherent set of assumptions, computed on today's figures.
Estimated price (USD)
| Estimated price | Bear | Base | Bull |
|---|---|---|---|
| 1 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
| 3 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
| 5 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
AI analysis
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
In brief
DNA X, Inc. (formerly Sonim Technologies) exited its phone and hotspot business and now focuses on its cryptocurrency trading platform, which was closed to the public in March 2026 for development and is due to relaunch in the fourth quarter of 2026. The key question is whether the platform can return to meaningful trading volume after relaunch, while commission revenue is still very small.
SWOT
Strengths
- The platform is run by a small team with controlled administrative costs and a fee structure that is competitive against larger rivals.
- The exit from the phone business leaves the company focused on a single product and has reduced its debts.
- Users can copy existing strategies, and the history of strategies can help develop new products.
Weaknesses
- Commission revenue has been very small during operation, and the platform does not yet have a significant trading volume.
- Administrative expenses have remained high, and the company depends on new financing to cover losses.
- The platform was taken offline to the public in 2026, which interrupted revenue generation.
Opportunities
- Adding new cryptocurrencies and products such as lending or staking could attract new customers and additional commissions.
- A successful relaunch in 2026 could bring volumes back toward early-2026 levels.
- If regulation becomes clearer, the platform could expand the range of assets it offers for trading.
Threats
- Cryptocurrency price volatility could suddenly reduce trading volume and commissions.
- Securities and commodities regulation could impose costly changes or restrictions.
- Competition from larger platforms with greater resources could limit growth.
Risks
- Dependence on cryptocurrency volatilityhigh
Price declines can reduce volumes and commissions, and revenue is highly sensitive to these swings.
- Liquidity and financinghigh
The company has raised funds through equity and debt, and if it could not obtain further financing, its activity could be affected.
- Legal classification of assetshigh
If authorities consider some traded cryptocurrencies to be securities, the company could face investigations or sanctions.
- Platform relaunchmedium
A delay in the relaunch planned for the fourth quarter of 2026 could postpone expected revenue.
- Nasdaq listing compliancemedium
The company was previously notified that it did not meet the stockholders' equity requirement; if compliance is not sustained, its listing could be affected.
Investment thesis
What would need to be true (bull case)
- If the platform relaunch brings volumes back toward early-2026 levels, commission income could rise significantly from current levels.
- Removing the phone business could allow resources to be concentrated on a single product.
- If new lending and staking products attract users, the company could diversify its revenue sources.
What would break the thesis
- Revenue remains very small, and the platform has not yet shown a sustained trading volume.
- The company depends on repeated financing, and administrative costs stayed high in 2026.
- Regulatory changes or further declines in cryptocurrency prices could again reduce activity.
What to watch
- Relaunch of the DNA X platform and trading volumeQ4 2026
- Monthly commission levels after relaunch2027
- Administrative expenses after the staff reductionQ3 2026
- Remaining 1.5 mn USD asset sale paymentOctober 2026
Products, market & competition
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
The business
DNA X, Inc. provides cryptocurrency trading services to individual traders worldwide through the website dnax.us. The platform lets users buy and sell cryptocurrencies for cash or cash equivalents and swap one cryptocurrency for another, and users can automate strategies across pairs of coins. The company says it does not take custody of customers' crypto assets, and its revenue comes from commissions, which are usually a fixed rate of 0.4% of volume 1. Since January 2026 the company's main activity has been operating the DNA X platform, after the sale of its phone and hotspot assets 2.
Segments
DNA X trading platform
The platform generated trading volume of 6,721 thousand USD in December 2025 and very modest commissions, and commission revenue averaged 47 USD per month in January and February 2026 12. Cost of revenue is fixed at 50% of commission revenue, and the company took the public site offline in March 2026 to develop new features 2.
Phone and hotspot business (discontinued)
Former Sonim Technologies designed and manufactured cell phones and mobile hotspots. The assets were sold to Pace Car Acquisition LLC on January 23, 2026 for 15.0 mn USD in cash before working capital adjustments 1. The results of this business are presented as discontinued operations 1.
Market context
The company operates in the cryptocurrency trading market, where prices are highly volatile and trading volumes depend on investor interest. Management said the fall in cryptocurrency values since October 2025 had a negative effect on trading volume 1. The company's market share is not stated in the sources, and its platform is at an early stage.
Trends
- Regulation of digital assetsmixed
The status of many cryptocurrencies as securities or commodities remains uncertain, and regulators have taken shifting positions; if rules become clearer, platforms could gain more predictability.
- Cryptocurrency price volatilityheadwind
Volatility directly affects trading volumes and therefore the platform's commission income; periods of price decline have reduced activity.
- AI-related featurestailwind
The company describes the platform as being extended with AI technologies to automate strategies; if these features attract new users, they could support growth.
- Access to fundingheadwind
The company has raised capital through equity and convertible instruments, which shows continued high reliance on external financing.
Competitive position
The company operates in a highly competitive environment in which customers choose among many trading platforms. Management says it has set fees lower than its larger competitors and seeks to implement features similar to other platforms 1. Limited marketing spending means its visibility relative to competitors is low.
- Large cryptocurrency trading platforms
Larger companies offering crypto trading and exchange, with higher fees than DNA X.
- Automated trading platforms
Services that offer automated strategies across coin pairs, directly competing with DNA X features.
- International crypto exchanges
Global operators attracting the same individual traders from outside the United States.
- Trading technology providers
Applications offering simulation and strategy tools similar to DNA X's simulation features.
Links, dependencies and risks
Who the company is tied to, from its own SEC filings (customers, suppliers, production, partners, competitors, countries, regulation), from the 5 %+ holders' statements (13D/13G) and from what other companies say about it. Click a node for its evidence; on a listed company the graph moves to it.
Loading the links…
News & filings
In the press
No news in our archive over the last 180 days.
SEC filings
- Current report31 Aug 2026Other events
- Current report27 Aug 2026Departure or appointment of officers
- Quarterly report19 Aug 2026
- Current report (amendment)13 Aug 2026Item 3.02 · Other events
- Current report (amendment)09 Jul 2026Item 3.02 · Item 3.03 · Amendments to articles or bylaws · Other events
- Current report02 Jul 2026Material agreement · Item 3.02 · Item 3.03 · Amendments to articles or bylaws · Financial statements and exhibits
- Current report04 Jun 2026Termination of a material agreement · Financial statements and exhibits
- Current report27 May 2026Material agreement · Creation of a direct financial obligation · Delisting notice · Item 3.02 · Financial statements and exhibits
- Quarterly report20 May 2026
- Current report20 May 2026Results of operations · Financial statements and exhibits
Sources
- [1] Form 10-K, fiscal year ended 2025-12-31 · SEC / DNA X, Inc. · 15 Apr 2026
- [2] Form 10-Q, quarter ended 2026-06-30 · SEC / DNA X, Inc. · 19 Aug 2026
- [3] Form 8-K, results release (exhibit 99.1) · SEC / DNA X, Inc. · 20 May 2026
Figures computed by olivLaw from SEC filings and closing prices; the qualitative analysis is AI-generated from cited sources. Not investment advice.